ZYVERSA THERAPEUTICS INC (ZVSA) Stock Price, Quote, News and Overview
NASDAQ:ZVSA - Nasdaq - US98987D3008 - Common Stock - Currency: USD
ZVSA Quote, Performance and Key Statistics
ZYVERSA THERAPEUTICS INC
NASDAQ:ZVSA (2/5/2025, 11:23:52 AM)
1.31
+0.03 (+2.34%)
The current stock price of ZVSA is 1.31 USD. In the past month the price increased by 3.23%. In the past year, price decreased by -78.07%.
ZVSA Latest News, Press Releases and Analysis
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Attend JPM’s Healthcare Conference 2025 in San Francisco
ZyVersa looks forward to meeting with investors and potential collaborators at JPM 2025 to discuss our technology, pipeline, and development milestones. ...
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Stroke-related cardiovascular injury and dysfunction are induced by AIM2 inflammasome activation in the heart, which can be blocked by ZyVersa's IC 100. ...
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
ZVSA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.95 | 338.97B | ||
| AMGN | AMGEN INC | 15.36 | 163.66B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 958.28 | 125.86B | ||
| GILD | GILEAD SCIENCES INC | 22.6 | 124.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.51 | 77.78B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.52B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.63B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.44B | ||
| NTRA | NATERA INC | N/A | 23.29B | ||
| BIIB | BIOGEN INC | 8.97 | 21.33B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.73 | 15.99B |
Related stock screener links
About ZVSA
Company Profile
Zyversa Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Weston, Florida and currently employs 7 full-time employees. The company went IPO on 2021-12-21. ZyVersa Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The firm is focused on leveraging advanced technologies to develop drugs for patients with chronic renal or inflammatory diseases. Its lead renal drug candidate Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or 2HBCD) is in development to treat multiple renal indications. Its lead anti-inflammatory drug candidate, Inflammasome ASC Inhibitor IC 100, is a humanized monoclonal antibody in development to treat multiple inflammatory diseases. Its renal pipeline is initially focused on rare, chronic glomerular diseases. Its lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS). VAR 200’s active ingredient, 2HBCD, is comprised of seven sugar molecules bound together in a 3-D ring with a hydrophobic core and hydrophilic exterior. VAR 200 mediates cholesterol efflux both passively and actively by interacting with hydrophilic components of the glomerular membrane.
Company Info
ZYVERSA THERAPEUTICS INC
2200 N. Commerce Parkway, Suite 208
Weston FLORIDA US
Employees: 7
Company Website: https://www.zyversa.com/
Investor Relations: https://investors.zyversa.com/
Phone: 17542311688
ZVSA FAQ
What is the stock price of ZVSA?
The current stock price of ZVSA is 1.31 USD.
What is the symbol for ZYVERSA THERAPEUTICS INC stock?
The exchange symbol of ZYVERSA THERAPEUTICS INC is ZVSA and it is listed on the Nasdaq exchange.
On which exchange is ZVSA stock listed?
ZVSA stock is listed on the Nasdaq exchange.
Is ZVSA a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ZVSA, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ZVSA.
Does ZVSA stock pay dividends?
ZVSA does not pay a dividend.
What is the Price/Earnings (PE) ratio of ZVSA?
ZVSA does not have a PE ratio as the earnings reported over the last twelve months were negative (-147.07).
What is the Short Interest ratio of ZVSA stock?
The outstanding short interest for ZVSA is 11.83% of its float.
ZVSA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ZVSA. When comparing the yearly performance of all stocks, ZVSA is a bad performer in the overall market: 94.42% of all stocks are doing better.
ZVSA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ZVSA. While ZVSA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ZVSA Financial Highlights
Over the last trailing twelve months ZVSA reported a non-GAAP Earnings per Share(EPS) of -147.07. The EPS increased by 96.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -109.81% | ||
| ROE | -303.53% | ||
| Debt/Equity | 0 |
ZVSA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ZVSA. The Buy consensus is the average rating of analysts ratings from 8 analysts.